Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

BACKGROUND: Patients with chronic viral infections including human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) are at increased risk of developing malignancies. The safety and efficacy of ICI therapy in patients with both cancer and chronic viral infections is not well esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Neil J., Al-Shbool, Ghassan, Blackburn, Matthew, Cook, Michael, Belouali, Anas, Liu, Stephen V., Madhavan, Subha, He, Aiwu Ruth, Atkins, Michael B., Gibney, Geoffrey T., Kim, Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918622/
https://www.ncbi.nlm.nih.gov/pubmed/31847881
http://dx.doi.org/10.1186/s40425-019-0771-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918622/
https://www.ncbi.nlm.nih.gov/pubmed/31847881
http://dx.doi.org/10.1186/s40425-019-0771-1

Ejemplares similares